Teva Pharmaceutical Industries Limited (TEVA) Balance Sheet
TEVA balance sheet, 2025
December 31, 2025 · U.S. dollars$40.75B assets = $32.83B liabilities + $7.91B equity
Both columns are drawn to the same scale: what TEVA owns equals what it owes plus shareholders’ equity. Hover a block for its value.
TEVA financial health
Descriptive bands, not a rating. Fiscal 2025.
TEVA balance sheet trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $92.89B2016 | $40.75B2025 | −8.7%/yr | |
| Total liabilities | $57.90B2016 | $32.83B2025 | −6.1%/yr | |
| Shareholders’ equity | $33.34B2016 | $7.91B2025 | −14.8%/yr | |
| Cash & short-term investments | $988.0M2016 | $3.56B2025 | +15.3%/yr | |
| Total debt | $35.80B2016 | $17.38B2025 | −7.7%/yr | |
| Net cash (debt) | −$34.81B2016 | −$13.83B2025 | +$21.0B | |
| Working capital | −$1.56B2016 | $490.0M2025 | +$2.0B | |
| Book value per share | $34.692016 | $6.742025 | −16.6%/yr | |
| Current ratio | 0.922016 | 1.042025 | +0.12 | |
| Debt / equity | 1.072016 | 2.202025 | +1.12 | |
| Shares outstanding | 961.0M2016 | 1.17B2025 | +2.2%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
TEVA assets
TEVA liabilities and equity
TEVA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
TEVA balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $3.56B | $3.30B | $3.23B | $2.80B | $2.17B | $2.18B | $1.98B | $1.78B | $963.0M | $988.0M |
| Cash & equivalents | $3.56B | $3.30B | $3.23B | $2.80B | $2.17B | $2.18B | $1.98B | $1.78B | $963.0M | $988.0M |
| Short-term investments | — | — | — | — | — | — | $957.0M | $991.0M | $17.0M | $10.0M |
| Receivables | $3.71B | $3.06B | $3.41B | $3.70B | $4.53B | $4.58B | $5.68B | $5.82B | $7.13B | $7.52B |
| Inventory | $3.18B | $3.01B | $4.02B | $3.83B | $3.82B | $4.40B | $4.42B | $4.73B | $4.92B | $4.95B |
| Other current assets | $3.50B | $3.19B | $1.83B | $1.72B | $2.06B | $1.84B | $1.39B | $1.46B | $2.37B | $3.50B |
| Total current assets | $13.95B | $12.55B | $12.48B | $12.05B | $12.57B | $13.01B | $13.46B | $13.79B | $15.38B | $16.96B |
| Property, plant & equipment (net) | $4.42B | $4.95B | $6.15B | $6.16B | $6.48B | $6.85B | $6.95B | $6.87B | $7.67B | $8.07B |
| Goodwill & intangible assets | $19.78B | $19.57B | $22.56B | $23.90B | $27.51B | $29.55B | $36.08B | $38.92B | $46.05B | $65.90B |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $61.0M | $83.0M | $283.0M |
| Other non-current assets | $2.60B | $2.26B | $2.28B | $1.90B | $1.11B | $1.23B | $978.0M | $1.04B | $1.42B | $1.68B |
| Total assets | $40.75B | $39.33B | $43.48B | $44.01B | $47.67B | $50.64B | $57.47B | $60.68B | $70.61B | $92.89B |
| Liabilities | ||||||||||
| Accounts payable | $2.53B | $2.20B | $2.60B | $1.89B | $1.69B | $1.76B | $1.72B | $1.85B | $2.07B | $2.16B |
| Short-term debt | $1.82B | $1.78B | $1.67B | $2.11B | $1.43B | $3.19B | $2.35B | $2.22B | $3.65B | $3.28B |
| Deferred revenue | — | — | $4.91B | $1.45B | $7.01B | $7.29B | $8.72B | $9.45B | $11.44B | $725.0M |
| Total current liabilities | $13.46B | $12.80B | $12.25B | $11.47B | $11.03B | $13.16B | $13.67B | $14.32B | $17.92B | $18.52B |
| Long-term debt | $14.99B | $16.00B | $18.16B | $19.10B | $21.62B | $22.73B | $24.56B | $26.70B | $28.83B | $32.52B |
| Lease obligations | $288.0M | $296.0M | $320.0M | $349.0M | $416.0M | $479.0M | $435.0M | — | — | — |
| Other long-term liabilities | $4.39B | $4.81B | $4.95B | $4.84B | $3.78B | $3.68B | $4.17B | $3.87B | $5.12B | $6.86B |
| Total liabilities | $32.83B | $33.61B | $35.35B | $35.41B | $36.42B | $39.58B | $42.41B | $44.89B | $51.87B | $57.90B |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $58.0M | $58.0M | $57.0M | $57.0M | $57.0M | $57.0M | $56.0M | $56.0M | $23.53B | $54.0M |
| Retained earnings (deficit) | −$13.76B | −$15.17B | −$13.53B | −$12.97B | −$10.53B | −$10.95B | −$6.96B | −$5.96B | −$3.80B | $13.61B |
| Treasury stock | — | — | — | — | −$4.13B | −$4.13B | −$4.13B | −$4.14B | −$4.15B | −$4.19B |
| Accumulated other comprehensive income | −$2.39B | −$3.15B | −$2.70B | −$2.84B | −$2.68B | −$2.40B | −$2.31B | −$2.46B | −$1.85B | −$3.16B |
| Minority interest | $4.0M | $347.0M | $620.0M | $794.0M | $966.0M | $1.03B | $1.09B | $1.09B | $1.39B | — |
| Total shareholders' equity | $7.91B | $5.37B | $7.51B | $7.80B | $10.28B | $10.03B | $13.97B | $14.71B | $17.36B | $33.34B |
| Key figures | ||||||||||
| Total debt | $17.38B | $18.08B | $20.15B | $21.56B | $23.46B | $26.40B | $27.34B | $28.92B | $32.48B | $35.80B |
| Net cash (debt) | −$13.83B | −$14.78B | −$16.93B | −$18.76B | −$21.29B | −$24.22B | −$25.37B | −$27.13B | −$31.51B | −$34.81B |
| Working capital | $490.0M | −$244.0M | $238.0M | $582.0M | $1.55B | −$159.0M | −$210.0M | −$528.0M | −$2.54B | −$1.56B |
| Tangible book value | −$11.87B | −$14.19B | −$15.06B | −$16.10B | −$17.23B | −$19.52B | −$22.11B | −$24.21B | −$28.70B | −$32.56B |
| Book value per share | $6.74 | $4.75 | $6.71 | $7.03 | $9.28 | $9.16 | $12.81 | $14.40 | $17.09 | $34.69 |
| Shares outstanding | 1.17B | 1.13B | 1.12B | 1.11B | 1.11B | 1.09B | 1.09B | 1.02B | 1.02B | 961.0M |
| Current ratio | 1.04 | 0.98 | 1.02 | 1.05 | 1.14 | 0.99 | 0.98 | 0.96 | 0.86 | 0.92 |
| Quick ratio | 0.54 | 0.50 | 0.54 | 0.57 | 0.61 | 0.51 | 0.56 | 0.53 | 0.45 | 0.46 |
| Debt / equity | 2.20 | 3.36 | 2.68 | 2.76 | 2.28 | 2.63 | 1.96 | 1.97 | 1.87 | 1.07 |
| Equity / assets | 19.4% | 13.7% | 17.3% | 17.7% | 21.6% | 19.8% | 24.3% | 24.2% | 24.6% | 35.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $3.65B | $3.74B | $3.56B | $2.20B | $2.16B | $1.70B | $3.30B | $3.32B | $2.26B | $2.99B | $3.23B | $2.25B |
| Cash & equivalents | $3.65B | $3.74B | $3.56B | $2.20B | $2.16B | $1.70B | $3.30B | $3.32B | $2.26B | $2.99B | $3.23B | $2.25B |
| Receivables | $3.49B | $3.39B | $3.71B | $3.81B | $3.56B | $3.38B | $3.06B | $3.46B | $3.77B | $3.46B | $3.41B | $3.38B |
| Inventory | $3.22B | $3.18B | $3.18B | $3.32B | $3.50B | $3.25B | $3.01B | $3.96B | $3.93B | $3.95B | $4.02B | $4.05B |
| Other current assets | $3.39B | $3.40B | $3.50B | $3.40B | $3.40B | $3.20B | $3.19B | $1.57B | $1.68B | $1.90B | $1.83B | $1.74B |
| Total current assets | $13.76B | $13.71B | $13.95B | $12.74B | $12.62B | $11.53B | $12.55B | $12.31B | $11.63B | $12.30B | $12.48B | $11.43B |
| Property, plant & equipment (net) | $4.26B | $4.33B | $4.42B | $5.16B | $5.17B | $4.99B | $4.95B | $6.04B | $5.93B | $5.98B | $6.15B | $6.03B |
| Goodwill & intangible assets | $19.29B | $19.43B | $19.78B | $19.88B | $20.09B | $19.67B | $19.57B | $20.88B | $21.34B | $22.06B | $22.56B | $22.41B |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $2.55B | $2.57B | $2.60B | $2.08B | $2.25B | $2.23B | $2.26B | $2.53B | $2.43B | $2.43B | $2.28B | $2.23B |
| Total assets | $39.86B | $40.04B | $40.75B | $39.86B | $40.13B | $38.41B | $39.33B | $41.76B | $41.34B | $42.77B | $43.48B | $42.09B |
| Liabilities | ||||||||||||
| Accounts payable | $2.72B | $2.60B | $2.53B | $2.35B | $2.50B | $2.29B | $2.20B | $2.37B | $2.37B | $2.44B | $2.60B | $2.28B |
| Short-term debt | $4.50B | $2.61B | $1.82B | $24.0M | $464.0M | $421.0M | $1.78B | $2.58B | $2.09B | $3.06B | $1.67B | $1.48B |
| Deferred revenue | — | — | — | — | — | — | — | — | — | — | $6.92B | $6.62B |
| Total current liabilities | $15.65B | $13.53B | $13.46B | $11.49B | $11.86B | $11.16B | $12.80B | $13.80B | $13.04B | $13.79B | $12.25B | $11.39B |
| Long-term debt | $12.09B | $14.02B | $14.99B | $16.77B | $16.76B | $16.23B | $16.00B | $16.40B | $16.55B | $16.58B | $18.16B | $18.50B |
| Lease obligations | $282.0M | $280.0M | $288.0M | $283.0M | $296.0M | $288.0M | $296.0M | $295.0M | $281.0M | $294.0M | $320.0M | $324.0M |
| Other long-term liabilities | $4.36B | $4.26B | $4.39B | $4.34B | $4.67B | $4.76B | $4.81B | $5.18B | $5.19B | $4.85B | $4.95B | $4.69B |
| Total liabilities | $32.10B | $31.81B | $32.84B | $32.60B | $33.30B | $32.15B | $33.61B | $35.37B | $34.77B | $35.23B | $35.35B | $34.58B |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | −$4.07B | −$4.07B | $58.0M | $58.0M | $58.0M | $58.0M | $58.0M | $58.0M | $58.0M | $58.0M | $57.0M | $57.0M |
| Retained earnings (deficit) | −$13.97B | −$13.39B | −$13.76B | −$14.24B | −$14.68B | −$14.96B | −$15.17B | −$14.96B | −$14.52B | −$13.67B | −$13.53B | −$13.87B |
| Accumulated other comprehensive income | −$2.46B | −$2.51B | −$2.39B | −$2.48B | −$2.43B | −$2.67B | −$3.15B | −$2.77B | −$2.88B | −$2.77B | −$2.70B | −$2.91B |
| Minority interest | $4.0M | $4.0M | $4.0M | $4.0M | $7.0M | — | — | — | — | — | — | — |
| Total shareholders' equity | $7.76B | $8.23B | $7.91B | $7.25B | $6.83B | $6.26B | $5.37B | $6.07B | $6.36B | $7.28B | $7.51B | $6.93B |
| Key figures | ||||||||||||
| Total debt | $16.87B | $16.91B | $17.38B | $17.09B | $17.52B | $16.94B | $18.08B | $19.27B | $18.92B | $19.94B | $20.15B | $20.30B |
| Net cash (debt) | −$13.22B | −$13.17B | −$13.83B | −$14.89B | −$15.36B | −$15.24B | −$14.78B | −$15.96B | −$16.66B | −$16.95B | −$16.93B | −$18.05B |
| Working capital | −$1.89B | $178.0M | $490.0M | $1.25B | $759.0M | $371.0M | −$244.0M | −$1.48B | −$1.41B | −$1.50B | $238.0M | $31.0M |
| Tangible book value | −$11.53B | −$11.20B | −$11.87B | −$12.63B | −$13.26B | −$13.40B | −$14.19B | −$14.81B | −$14.98B | −$14.79B | −$15.06B | −$15.48B |
| Book value per share | $6.57 | $6.98 | $6.74 | $6.23 | $5.88 | $5.40 | $4.74 | $5.35 | $5.61 | $6.48 | $6.60 | $6.10 |
| Shares outstanding | 1.18B | 1.18B | 1.17B | 1.16B | 1.16B | 1.16B | 1.13B | 1.13B | 1.13B | 1.12B | 1.14B | 1.14B |
| Current ratio | 0.88 | 1.01 | 1.04 | 1.11 | 1.06 | 1.03 | 0.98 | 0.89 | 0.89 | 0.89 | 1.02 | 1.00 |
| Quick ratio | 0.46 | 0.53 | 0.54 | 0.52 | 0.48 | 0.46 | 0.50 | 0.49 | 0.46 | 0.47 | 0.54 | 0.49 |
| Debt / equity | 2.18 | 2.05 | 2.20 | 2.36 | 2.57 | 2.71 | 3.36 | 3.18 | 2.98 | 2.74 | 2.68 | 2.93 |
| Equity / assets | 19.5% | 20.5% | 19.4% | 18.2% | 17.0% | 16.3% | 13.7% | 14.5% | 15.4% | 17.0% | 17.3% | 16.5% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed February 3, 2026); data from EODHD.
TEVA financial position
At the end of fiscal 2025 (December 31, 2025), Teva Pharmaceutical Industries had total assets of $40.7 billion (up 3.6% from a year earlier), total liabilities of $32.8 billion and shareholders' equity of $7.9 billion. It held $3.6 billion in cash and short-term investments against $17.4 billion of debt, net debt of $13.8 billion. Its current ratio was 1.04. In the latest quarter (ended June 30, 2026) total assets were $39.9 billion and equity $7.8 billion.
Related: TEVA income statement, TEVA cash flow statement, TEVA key metrics. See the TEVA stock overview for the latest quote and news.
TEVA balance sheet FAQ
What are Teva Pharmaceutical Industries's total assets?
Teva Pharmaceutical Industries reported total assets of $40.7 billion at the end of fiscal 2025 (December 31, 2025), compared with $39.3 billion a year earlier.
How much debt does Teva Pharmaceutical Industries have?
Teva Pharmaceutical Industries had $17.4 billion of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 2.20.
How much cash does Teva Pharmaceutical Industries have?
Teva Pharmaceutical Industries held $3.6 billion in cash and short-term investments at the end of fiscal 2025; with $17.4 billion of debt that is net debt of $13.8 billion.
What is Teva Pharmaceutical Industries's book value?
Teva Pharmaceutical Industries's shareholders' equity (book value) was $7.9 billion at the end of fiscal 2025, or $6.74 per share.
What is Teva Pharmaceutical Industries's current ratio?
Teva Pharmaceutical Industries had current assets of $13.9 billion and current liabilities of $13.5 billion, a current ratio of 1.04 (it can cover its short-term obligations).
How much goodwill does Teva Pharmaceutical Industries have?
Teva Pharmaceutical Industries carried $19.8 billion of goodwill and intangible assets, 48.5% of total assets, at the end of fiscal 2025.